Sutherland Edward L, Choromanska Agnieszka, Al-Katib Sayf, Coffey Mary
Department of Diagnostic Radiology, William Beaumont Hospital, 3601 W 13 Mile Rd, Royal Oak, MI, 48073, USA.
Beaumont Health Research Institute, 3601 W 13 Mile Rd, Royal Oak, MI, 48073, USA.
J Ultrasound. 2018 Jun;21(2):99-104. doi: 10.1007/s40477-018-0299-0. Epub 2018 Apr 25.
The purpose of this study was to evaluate the rate of nondiagnostic ultrasound-guided renal mass biopsies (RMBs) at our institution and to determine what patient, procedural, and focal renal mass (FRM) factors were associated with nondiagnostic ultrasound-guided RMBs.
Eighty-two ultrasound-guided renal mass biopsies performed between January 2014 and October 2016 were included in our study. Biopsy outcomes (diagnostic vs. nondiagnostic) and patient, procedural, and FRM characteristics were retrospectively reviewed and recorded. Univariate statistical analyses were performed to identify biopsy characteristics that were indicative of nondiagnostic biopsy.
Ultrasound-guided RMBs were diagnostic in 70 out of 82 cases (85%) and non-diagnostic in 12 cases (15%). Among the diagnostic biopsies, 54 (77%) were malignant cases, 94% of which were renal cell carcinoma (RCC). Of the 12 nondiagnostic cases, the final diagnosis was RCC in 4 cases and angiomyolipoma in one case; seven of the nondiagnostic cases were lost to follow-up. A weak association (p = 0.04) was found between the number of needle passes and the biopsy outcome. None of the remaining collected RMB characteristics showed a significant correlation with a diagnostic or nondiagnostic RMB. Six patients (7%) experienced complications.
Ultrasound-guided renal mass biopsy is a safe and effective method for the diagnosis of renal masses with a low rate of nondiagnostic outcomes. A nondiagnostic biopsy should not be treated as a surrogate for a diagnosis since a significant number of patients with nondiagnostic biopsies have subsequently been shown to have renal malignancies. Repeat biopsy should be considered in such cases.
本研究旨在评估我院超声引导下肾肿物活检(RMB)的非诊断率,并确定哪些患者、操作及局灶性肾肿物(FRM)因素与超声引导下非诊断性RMB相关。
纳入2014年1月至2016年10月期间进行的82例超声引导下肾肿物活检。回顾性审查并记录活检结果(诊断性与非诊断性)以及患者、操作和FRM特征。进行单因素统计分析以确定指示非诊断性活检的活检特征。
82例病例中,70例(85%)超声引导下RMB为诊断性,12例(15%)为非诊断性。在诊断性活检中,54例(77%)为恶性病例,其中94%为肾细胞癌(RCC)。12例非诊断性病例中,最终诊断为RCC的有4例,血管平滑肌脂肪瘤1例;7例非诊断性病例失访。穿刺针数与活检结果之间存在弱相关性(p = 0.04)。其余收集的RMB特征均未显示与诊断性或非诊断性RMB有显著相关性。6例患者(7%)出现并发症。
超声引导下肾肿物活检是诊断肾肿物的一种安全有效的方法,非诊断性结果发生率低。不应将非诊断性活检视为诊断的替代方法,因为大量非诊断性活检患者随后被证明患有肾恶性肿瘤。此类病例应考虑重复活检。